Literature DB >> 27184905

Metabolomic profiling reveals distinct patterns of tricarboxylic acid disorders in blood stasis syndrome associated with coronary heart disease.

Yong Wang1, Chun Li2, Hong Chang1, Ling-Hui Lu1, Qi Qiu3, Yu-Lin Ouyang1, Jun-da Yu4, Shu-Zhen Guo1, Jing Han1, Wei Wang5.   

Abstract

OBJECTIVE: To investigate the underlying metabolomic profifiling of coronary heart disease (CHD) with blood stasis syndrome (BSS).
METHODS: CHD model was induced by a nameroid constrictor in Chinese miniature swine. Fifteen miniature swine were randomly divided into a model group (n=9) and a control group (n=6), respectively according to arandom number table. After 4 weeks, plasma hemorheology was detected by automatic hemorheological analyzer, indices including hematocrit, plasma viscosity, blood viscosity, rigidity index and erythrocyte sedimentation rate; cardiac function was assessed by echocardiograph to detect left ventricular end-systolic diameter (LVED), left ventricular end-diastolic diameter (LVEDd), ejection fraction (EF), fractional shortening (FS) and other indicators. Gas chromatography coupled with mass spectrometry (GC-MS) and bioinformatics were applied to analyze spectra of CHD plasma with BSS.
RESULTS: The results of hemorheology analysis showed signifificant changes in viscosity, with low shear whole blood viscosity being lower and plasma viscosity higher in the model group compared with the control group. Moreover, whole blood reduction viscosity at high shear rate and whole blood reduction viscosity at low shear rate increased signifificantly (P <0.05). The echocardiograph results demonstrated that cardiac EF and FS showed signifificant difference (P <0.05), with EF values being decreased to 50% or less. The GC-MS data showed that principal component analysis can clearly separate the animals with BSS from those in the control group. The enriched Kyoto Encyclopedia of Genes and Genomes biological pathways results suggested that the patterns involved were associated with dysfunction of energy metabolism including glucose and lipid disorders, especially in glycolysis/gluconeogenesis, galactose metabolism and adenosine-triphosphate-binding cassette transporters.
CONCLUSIONS: Glucose metabolism and lipid metabolism disorders were the major contributors to the syndrome classifification of CHD with BSS.

Entities:  

Keywords:  Chinese medicine; blood stasis syndrome; coronary heart disease; metabolomic profiling

Mesh:

Substances:

Year:  2016        PMID: 27184905     DOI: 10.1007/s11655-015-2401-1

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  21 in total

Review 1.  Metabonomics: a platform for studying drug toxicity and gene function.

Authors:  Jeremy K Nicholson; John Connelly; John C Lindon; Elaine Holmes
Journal:  Nat Rev Drug Discov       Date:  2002-02       Impact factor: 84.694

2.  [Establishment and evaluation on miniature pig model of ischemic coronary heart disease with qi-deficiency and blood-stasis syndrome].

Authors:  Yong Wang; Chun Li; Wen-Jing Chuo
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2011-02

Review 3.  The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball?

Authors:  Julian L Griffin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-01-29       Impact factor: 6.237

4.  Correlation of ischemic area and coronary flow with ameroid size in a porcine model.

Authors:  Egemen Tuzun; Eddie Oliveira; Cuneyt Narin; Hassan Khalil; Pilar Jimenez-Quevedo; Emerson Perin; Guilherme Silva
Journal:  J Surg Res       Date:  2009-04-19       Impact factor: 2.192

5.  Delayed onset of subendocardial diastolic thinning at rest identifies hypoperfused myocardium.

Authors:  Jianwen Wang; Theodore P Abraham; Josef Korinek; Stig Urheim; Eileen M McMahon; Marek Belohlavek
Journal:  Circulation       Date:  2005-05-31       Impact factor: 29.690

Review 6.  Surgical animal models of heart failure related to coronary heart disease.

Authors:  Rainer Klocke; Wen Tian; Michael T Kuhlmann; Sigrid Nikol
Journal:  Cardiovasc Res       Date:  2006-11-23       Impact factor: 10.787

7.  Metabolite profiling for plant functional genomics.

Authors:  O Fiehn; J Kopka; P Dörmann; T Altmann; R N Trethewey; L Willmitzer
Journal:  Nat Biotechnol       Date:  2000-11       Impact factor: 54.908

8.  [Effects of Xuefu Zhuyu Oral Liquid on hemorheology in patients with blood-stasis syndrome due to coronary disease and their relationship with human platelet antigen-3 polymorphism].

Authors:  Mei Xue; Ke-ji Chen; Xiao-juan Ma; Jian-gang Liu; Yue-rong Jiang; Yu Miao; Hui-jun Yin
Journal:  Zhong Xi Yi Jie He Xue Bao       Date:  2008-11

9.  Study on syndrome element characteristics and its correlation with coronary angiography in 324 patients with coronary heart disease.

Authors:  Jie WANG; Fu-yong CHU; Jun LI; Kui-wu YAO; Jing-bai ZHONG; Ke-hua ZHOU; Qing-yong HE; Xiao-wei SUN
Journal:  Chin J Integr Med       Date:  2008-12-12       Impact factor: 1.978

10.  Metabolite profiling of a NIST Standard Reference Material for human plasma (SRM 1950): GC-MS, LC-MS, NMR, and clinical laboratory analyses, libraries, and web-based resources.

Authors:  Yamil Simón-Manso; Mark S Lowenthal; Lisa E Kilpatrick; Maureen L Sampson; Kelly H Telu; Paul A Rudnick; W Gary Mallard; Daniel W Bearden; Tracey B Schock; Dmitrii V Tchekhovskoi; Niksa Blonder; Xinjian Yan; Yuxue Liang; Yufang Zheng; William E Wallace; Pedatsur Neta; Karen W Phinney; Alan T Remaley; Stephen E Stein
Journal:  Anal Chem       Date:  2013-12-03       Impact factor: 6.986

View more
  2 in total

1.  Bioinformatics analysis of microRNAs related to blood stasis syndrome in diabetes mellitus patients.

Authors:  Ruixue Chen; Minghao Chen; Ya Xiao; Qiuer Liang; Yunfei Cai; Liguo Chen; Meixia Fang
Journal:  Biosci Rep       Date:  2018-03-21       Impact factor: 3.840

2.  Combined Lipidomics and Network Pharmacology Study of Protective Effects of Salvia miltiorrhiza against Blood Stasis Syndrome.

Authors:  Yidian Jin; Zhiru Xie; Shasha Li; Xiangyu Zeng; Leqi Wang; Ping Hu; Hongyang Zhang; Xue Xiao
Journal:  Evid Based Complement Alternat Med       Date:  2021-03-19       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.